Angiotensin-(1-7) and Energy Expenditure in Human Obesity

StatusCompleted
PhaseEarly Phase 1
SponsorAmy Arnold
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Final enrollment: 27 participants (planned 30)
    • Primary completion date changed from estimate of Dec 2026 to Apr 15, 2026
    • Eligibility criteria expanded, about 25 words
  2. Primary and study completion dates: Dec 2025 to Dec 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v23
  3. Re-verified, no change to tracked fieldsv22
  4. Primary and study completion dates: Dec 2024 to Dec 2025
    • Site contact updated
    v21
  5. 2 versions Re-verified since Nov 2, 2023, no change to tracked fieldsv19-v20
Show 17 earlier versionsHide 17 earlier versions
  1. Primary and study completion dates: Dec 2023 to Dec 2024v18
  2. Primary and study completion dates: Sep 2023 to Dec 2023v17
  3. 2 versions Re-verified since Dec 12, 2021, no change to tracked fieldsv15-v16
  4. Primary and study completion dates: Sep 2022 to Sep 2023v14
  5. 6 versions Re-verified since Nov 4, 2019, no change to tracked fieldsv8-v13
  6. Trial status: Not Yet Recruiting to Recruitingv7 Show 4 more changesShow less
    • Primary completion date: Jul 2021 to Sep 2022
    • Study sites: 0 to 1
    • Study completion date: Jul 2022 to Sep 2022
    • Start date changed from estimate of Oct 2019 to Sep 26, 2019
  7. Start date: Jul 2019 to Oct 2019v6
  8. Enrollment target: 32 to 30
    • Primary completion date: Jun 2021 to Jul 2021
    • Study completion date: Jun 2022 to Jul 2022
    • Start date: Jun 2019 to Jul 2019
    v5
  9. Primary endpoints: 1 to 2
    • Enrollment target: 30 to 32
    • Secondary endpoints: 10 to 2
    • Study description expanded, about 2 words
    v4
  10. Re-verified, no change to tracked fieldsv3
  11. Secondary endpoints: details revised at 1 of 10 entries
    • Eligibility criteria expanded, about 2 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amy Arnold
1 trial monitored
See all monitored trials
Obesity
3,888 trials monitored
See 157 trials at risk
The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expenditure and promotes markers of heat production (thermogenesis) in white adipose tissue in human obesity.
Trial Details
NCT Number NCT03777215
Lead Sponsor Amy Arnold
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov